|
Manchester, United Kingdom, 13th October 2009 - Catalyst technologies company Reaxa has announced further investment to support development of its Nickel EnCat™ immobilised catalyst
To support growth and large scale EnCat™ production, UK investors Enterprise Ventures and YFM Private Equity are leading further investment in Reaxa.
Nickel Encat™ is now in trials at a major pharma player in preparation for bulk scale production of a high-volume API. Multiple-use Nickel EnCat™ catalyst delivers major gains in API process yield, reduced contamination levels and greater cost effectiveness, compared with the standard Raney™-type nickel catalysts. Nickel EnCat™ is an immobilised nickel catalyst that traps catalyst species in a porous polymer bead, preventing product and waste stream contamination. EnCat™ technology can be safer, simpler and cleaner than processes using Raney™/sponge nickel products – with re-use in multiple batches, driving down cost and metal consumption.
“Adoption of Nickel EnCat™ to significantly benefit large scale API production for a launched product is a highly significant milestone”, says Reaxa Sales Director Ed Dutton.
Nickel EnCat™ offers an exciting alternative for up to 20% of the pharma hydrogenation catalyst market. Reaxa’s 27-product range includes the EnCat™ family of 10 polymer- encapsulated catalysts and 17 QuadraPure™ and QuadraSil™ scavenging resins. Whereas standard catalysts typically result in over 1,000 parts per million of metal residues in the crude product, EnCat™ processes can often meet specification – less than 10 ppm – without further purification steps. With market acceptance of the company’s differentiated range of QuadraPure™ (polymer) and QuadraSil™ (silica) scavengers, Reaxa is now the market leader in metal extraction and purification technology for pharma manufacturing. |
